Verastem Inc (VSTM) - Total Liabilities
Based on the latest financial reports, Verastem Inc (VSTM) has total liabilities worth $156.53 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Verastem Inc (VSTM) investment intensity to see how much of total assets are deployed in long-term investments.
Verastem Inc - Total Liabilities Trend (2010–2025)
This chart illustrates how Verastem Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see VSTM total assets.
Verastem Inc Competitors by Total Liabilities
The table below lists competitors of Verastem Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Lifotronic Technology Co
SHG:688389
|
China | CN¥382.72 Million |
|
Velocity Financial Llc
NYSE:VEL
|
USA | $6.32 Billion |
|
Khang Dien House Trading and Investment JSC
VN:KDH
|
Vietnam | ₫18.34 Trillion |
|
Qian Jiang Water Resources Development Co Ltd
SHG:600283
|
China | CN¥5.65 Billion |
|
Xiangpiaopiao Food Co Ltd
SHG:603711
|
China | CN¥1.42 Billion |
|
Inly Media Co Ltd
SHG:603598
|
China | CN¥2.18 Billion |
|
FRoSTA AG
F:NLM
|
Germany | €217.82 Million |
|
ACNB Corporation
NASDAQ:ACNB
|
USA | $2.90 Billion |
Liability Composition Analysis (2010–2025)
This chart breaks down Verastem Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Verastem Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Verastem Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Verastem Inc (2010–2025)
The table below shows the annual total liabilities of Verastem Inc from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $189.25 Million | +45.09% |
| 2024-12-31 | $130.43 Million | +41.24% |
| 2023-12-31 | $92.34 Million | +93.76% |
| 2022-12-31 | $47.66 Million | +125.84% |
| 2021-12-31 | $21.10 Million | -45.99% |
| 2020-12-31 | $39.08 Million | -71.66% |
| 2019-12-31 | $137.87 Million | -9.85% |
| 2018-12-31 | $152.94 Million | +376.34% |
| 2017-12-31 | $32.11 Million | +183.33% |
| 2016-12-31 | $11.33 Million | +6.65% |
| 2015-12-31 | $10.62 Million | +7.51% |
| 2014-12-31 | $9.88 Million | +26.46% |
| 2013-12-31 | $7.82 Million | +218.07% |
| 2012-12-31 | $2.46 Million | -96.58% |
| 2011-12-31 | $71.80 Million | +19411.68% |
| 2010-12-31 | $368.00K | -- |
About Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAP… Read more